Patents by Inventor Wouter Van't Hof

Wouter Van't Hof has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11197889
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: December 14, 2021
    Assignees: ABT Holding Company, Oregon Health & Science University
    Inventors: Richard Maziarz, Magdalena Kovacsovics, Philip Streeter, Robert Deans, Wouter Van't Hof
  • Publication number: 20210346429
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Application
    Filed: July 12, 2021
    Publication date: November 11, 2021
    Applicants: ABT Holding Company, Oregon Health & Science University
    Inventors: Richard MAZIARZ, Magdalena KOVACSOVICS, Philip STREETER, Robert DEANS, Wouter VAN'T HOF
  • Publication number: 20210254010
    Abstract: Methods for isolating mesenchymal stromal cells from umbilical cord blood. The methods include providing a blood collection bag having raw umbilical cord blood contained therein, draining the umbilical cord blood from the blood collection bag, introducing a cell detachment solution into the blood collection bag to dissociate mesenchymal stromal cells adhered to the bag surface, thereby forming a mesenchymal stromal cell enriched fluid, and voiding the mesenchymal stromal cell enriched fluid into a collection apparatus for further processing and culturing.
    Type: Application
    Filed: May 31, 2019
    Publication date: August 19, 2021
    Inventors: Mary Laughlin, Jeong-Su Do, Wouter Van't Hof
  • Publication number: 20210228626
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Application
    Filed: April 9, 2021
    Publication date: July 29, 2021
    Applicants: ABT Holding Company, OREGON HEALTH & SCIENCE UNIVERISTY
    Inventors: Robert DEANS, Richard MAZIARZ, Magdalena KOVACSOVICS, Philip STREETER, Wouter VAN'T HOF
  • Publication number: 20210205359
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Application
    Filed: January 12, 2021
    Publication date: July 8, 2021
    Applicants: ABT Holding Company, OREGON HEALTH & SCIENCE UNIVERISTY
    Inventors: Robert Deans, Richard Maziarz, Magdalena Kovacsovics, Philip Streeter, Wouter Van't Hof
  • Patent number: 11000546
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: May 11, 2021
    Assignees: ATHERSYS, INC., OREGON HEALTH & SCIENCE UNIVERISTY
    Inventors: Robert Deans, Richard Maziarz, Magdalena Kovacsovics, Philip Streeter, Wouter Van't Hof
  • Publication number: 20180318346
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Application
    Filed: May 3, 2018
    Publication date: November 8, 2018
    Applicants: ATHERSYS, INC., OREGON HEALTH & SCIENCE UNIVERISTY
    Inventors: Robert DEANS, Richard MAZIARZ, Magdalena KOVACSOVICS, Philip STREETER, Wouter VAN'T HOF
  • Patent number: 9962407
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: May 8, 2018
    Assignees: Athersys, Inc., Oregon Health and Science University
    Inventors: Robert Deans, Wouter Van't Hof, Richard Maziarz, Magdalena Kovacsovics, Philip Streeter
  • Publication number: 20180055881
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Application
    Filed: November 6, 2017
    Publication date: March 1, 2018
    Applicants: ATHERSYS, INC., OREGON HEALTH AND SCIENCE UNIVERSITY
    Inventors: Richard MAZIARZ, Magdalena Kovacsovics, Philip Streeter, Robert Deans, Wouter Van't Hof
  • Patent number: 9808485
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Grant
    Filed: January 6, 2012
    Date of Patent: November 7, 2017
    Assignees: Athersys, Inc., Oregon Health And Science University
    Inventors: Richard Maziarz, Magdalena Kovacsovics, Philip Streeter, Robert Deans, Wouter Van't Hof
  • Publication number: 20150118193
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Application
    Filed: July 30, 2013
    Publication date: April 30, 2015
    Applicant: Oregon Health And Science University
    Inventors: Richard MAZIARZ, Magdalena KOVACSOVICS, Philip STREETER, Robert DEANS, Wouter VAN'T HOF
  • Publication number: 20140134137
    Abstract: The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in leukocytes. Downregulating expression of cellular adhesion molecules reduces leukocyte adhesion to endothelial cells such that extravasation is reduced. The end result is a reduction of inflammation. The cells are non-embryonic non-germ cells that have pluripotent characteristics. These may include expression of pluripotential markers and broad differentiation potential.
    Type: Application
    Filed: November 1, 2013
    Publication date: May 15, 2014
    Applicant: ABT Holding Company
    Inventor: Wouter Van't Hof
  • Publication number: 20140037596
    Abstract: The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in vascular endothelial cells. Downregulating expression of cellular adhesion molecules reduces leukocyte adhesion to the endothelial cells such that extravasation is reduced. The end result is a reduction of inflammation. The cells are non-embryonic non-germ cells that have pluripotent characteristics. These may include expression of pluripotential markers and broad differentiation potential.
    Type: Application
    Filed: October 10, 2013
    Publication date: February 6, 2014
    Applicant: ABT Holding Company
    Inventors: Juliana Megan WODA, Wouter VAN'T HOF
  • Publication number: 20120135043
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Application
    Filed: January 6, 2012
    Publication date: May 31, 2012
    Inventors: Richard MAZIARZ, Magdalena Kovacsovics, Philip Streeter, Robert Deans, Wouter Van't Hof
  • Patent number: 8147824
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Grant
    Filed: November 9, 2005
    Date of Patent: April 3, 2012
    Assignees: Athersys, Inc., Oregon Health and Science University
    Inventors: Richard Maziarz, Magdalena Kovacsovics, Philip Streeter, Robert Deans, Wouter Van't Hof
  • Publication number: 20110020293
    Abstract: The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in vascular endothelial cells. Downregulating expression of cellular adhesion molecules reduces leukocyte adhesion to the endothelial cells such that extravasation is reduced. The end result is a reduction of inflammation. The cells are non-embryonic non-germ cells that have pluripotent characteristics. These may include expression of pluripotential markers and broad differentiation potential.
    Type: Application
    Filed: July 21, 2010
    Publication date: January 27, 2011
    Applicant: ABT Holding Company
    Inventors: Juliana Megan Woda, Wouter Van't Hof
  • Publication number: 20110020292
    Abstract: The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in leukocytes. Downregulating expression of cellular adhesion molecules reduces leukocyte adhesion to endothelial cells such that extravasation is reduced. The end result is a reduction of inflammation. The cells are non-embryonic non-germ cells that have pluripotent characteristics. These may include expression of pluripotential markers and broad differentiation potential.
    Type: Application
    Filed: July 21, 2010
    Publication date: January 27, 2011
    Applicant: ABT Holding Company
    Inventor: Wouter Van't Hof
  • Publication number: 20060263337
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Application
    Filed: November 9, 2005
    Publication date: November 23, 2006
    Inventors: Richard Maziarz, Philip Streeter, Magdalena Kovacsovics, Robert Deans, Wouter Van't Hof